Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective
One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration. We’ve covered this before: The link between Semaglutide & vision loss (NAION)How deep is the link between GLP1s and possible vision loss? We examine
Here’s what happened last week in the GLP1 ecosystem: 🧑⚖️ Lawsuits over the negative side effects of GLP1s 🌐 The WHO is building a guideline for GLP1 use and requesting comments 🎭 Celebrity endorsements continue: Andy Cohen reveals use of GLP1s for weight management 🚨 GLP1 is now being used in SMS scams
We mostly hear of increased adoption of GLP1s in the mainstream — entertainers and public figures being quizzed on whether they use it or not, spectacular transformations for patients who have found a GLP1 that works for them, etc. Silicon Valley and those that like to experiment or “bio-hack” were very
Keeping track of negative side effects of GLP1s is just as important (if not more important) than keeping track of positive side effects. Cyclic Vomiting Syndrome is a *rare* negative side effect that doesn’t come up in the research very often, but after hearing anecdotal reports of this side
Here’s what happened last week in the GLP1 ecosystem: 🌎 World Health Organization (WHO) adds GLP1 to essential medicines list (for diabetes) 🏛️ FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S. 🧑⚖️ CVS Caremark gets sued for stopping coverage of GLP1s 📰 GLP-1 Receptor
Here’s what happened last week in the GLP1 ecosystem: 📑 Orforglipron Phase 3 trial results landed 📢 TEVA Pharmaceuticals announced FDA approval for weight loss with Liraglutide 🎤 Meghan Trainor has been in the news after a GLP1 transformation 🎾 Serena Williams has shared her GLP1 story Go deeper, read more Here are
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.